Rickey: You're off to a fine start. I'm a long-term holder of GALT
and have the luxury of Patience. Most investors don't. Incidentally
quite a while back I evaluated both GALT and LJPC, as they both were
targeting Galectin-3 against fibrosis. While the CEO of LJPC has a
PhD and MD from Stanford and a record of some success in start-ups,
I felt the capital structure of LJPC was unfavorable (bloated, though later improved) and the science available to LJPC was flimsy and second-rate. In sharp contrast Galt's science has its roots from
Harvard and still has connections there (first-rate at the level of
carbohydrate science). Further, and also of great importance, is the
quality of GALT's top people: Founder&Chairman Czirr is serious and
tenacious, and has invested heavily in the company, while CEO Traber, besides being a liver specialist, has top-notch experience in pharma industry. That Dr. Traber privately has a colorful sense
of humor is hardly an ipso facto detriment. An additional positive
quality of GALT is overall its level of transparency is much better than that of LJPC. Resultantly my decision to invest (substantively)
in GALT was easy, and the decision to ignore LJPC was equally easy.
At this juncture I'm writing to concur with your (Ricky)
perspective.
Let me also note here that a valuable contributor to the GALT message board I feel is Biotech2010. Pay attention to what he writes.
